A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2018
Price : $35 *
At a glance
- Drugs Pomalidomide (Primary) ; Cyclophosphamide; Dexamethasone; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 03 Oct 2018 Results (Data cut off 25 October 2017 ) of final analysis of the primary endpoint published in the Blood.
- 12 Dec 2017 Results (Data cut off July 4 2017) of intermediate analysis presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.